AngioDynamics Inc

AngioDynamics Q3 2026 results: $78.4 M sales, 8.9 % growth driven by Med Tech, EPS loss $0.19, raised 2026 guidance to $313–$316 M.

AngioDynamics reports a record‑breaking Q3 with double‑digit Med Tech sales growth, a revised upbeat full‑year outlook, and a strong cash position, boosting investor confidence in its high‑growth vascular device pipeline.

AngioDynamics Q2 2026 earnings forecast: EPS up 61.5 % to –$0.10, revenue to $76.4 M. Explore how the latest outlook could shape investor sentiment and stock movement.

AngioDynamics, Inc. drives medical innovation with diagnostic and interventional devices, yet faces profitability challenges—see how its strategy could reshape its market position and future growth prospects.

AngioDynamics Inc. reported strong Q1 2026 earnings, with revenue up 12.2% and EPS improving by 75%, leading the company to raise its full-year guidance and its stock price to gain 8-11% in intraday trading.

AngioDynamics Inc. is expected to report a loss of $0.12 per share in its Q1 earnings, with analysts projecting a year-to-date loss of $0.31 per share, raising concerns about the company’s financial trajectory and investor confidence.

AngioDynamics Inc. faces a critical earnings outlook, with analysts predicting a loss per share and revenue growth that falls short of previous year’s numbers, leaving the company’s future uncertain.

AngioDynamics Inc, a healthcare equipment company, faces significant financial turbulence despite its innovative products and commitment to improving patient outcomes.